Immatics imagines broader CAR-T pipeline with another Bristol Myers pact and addition to 2019 TCR deal
Immatics is hitting the gas pedal on another Bristol Myers Squibb deal as the biotech-Big Pharma pair also level up their 2019 pact, originally inked with Celgene.
While the German-Houston biotech is still in its early-stage clinical development days, Bristol Myers likes what it has seen and wants to dive deeper into Immatics’ T-cell therapy platforms. That includes $60 million upfront for a new deal and another $20 million now for an expansion to the 2019 collab.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.